Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Florida for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Florida only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Florida (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Syed Zafar (NPI 1811187909)

Field	Value
Entity Type	Individual
Organization	Syed Zafar
Address	8260 Gladiolus Dr
City	Fort Myers
State	FL
ZIP	33908
Taxonomy	Medical Oncology Physician
NPI Enumerated	July 26, 2007

Payer Source	Total Paid
Medicare	$6M
Medicaid	$0

Key Findings

SYED ZAFAR is a Medical Oncology Physician in FORT MYERS, FL with an NPI enumerated on 2007-07-26 (~19 years ago). The provider reports Total Medicare revenue of $6M and has no Medicaid billing on file, indicating an effectively single-payer footprint concentrated on Medicare beneficiaries.

Revenue is highly concentrated in three drugs: the precomputed top 3 Medicare codes by revenue account for 75.1% of this provider's Total Medicare revenue. Those top codes are J9271 ($3.1M revenue; 52.1% of this provider's total Medicare revenue), J9144 ($697.7K; 11.9%), and J9299 ($649.9K; 11.1%), which together dominate the practice’s Medicare receipts.

The code mix and volumes point to an outpatient infusion oncology operation focused on high-cost biologics and checkpoint inhibitors; key chemotherapy and biologic codes are J9271 (pembrolizumab), J9144 (daratumumab), and J9299 (nivolumab). Ancillary administration and chemotherapy codes such as 96413 (1.2K claims, $122K revenue), G0498 (230 claims, $30.6K), and 96365 (392 claims, $19.6K) show on-site infusion capability and continuity-of-care infusions that support a clinic-based infusion model.

Competitive standing is exceptional for pembrolizumab: J9271 ranks #3 of 1841 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), indicating this provider is a national outlier and a leading biller for that drug. By contrast, J9144 (rank #59 of 615, 90th percentile; typical, unremarkable) and J9299 (rank #94 of 505, 82th percentile; typical, unremarkable) are high-volume but not at the same dominant level, so the provider is nationally prominent specifically for J9271.

Several service and administration codes are also statistical outliers, consistent with high throughput of infusion visits and follow-up care: 96413 is listed as 100th percentile (extreme outlier), 99214 ranks in the 99th percentile (extreme outlier), and J0185 ranks #2 of 819 providers (100th percentile; extreme outlier). These outlier labels signal materially higher procedure volumes relative to national peers for both drug administration and associated office visit activity.

Payer mix is effectively single-payer Medicare: the dataset shows Total Medicare revenue of $6M and explicitly notes none below for Medicaid (no Medicaid billing on file). That concentration means the provider’s revenue base and payer negotiations are driven by Medicare beneficiaries and reimbursement policies rather than a blended Medicare/Medicaid book.

The presence of high-volume evaluation-and-management codes alongside infusion codes suggests an integrated practice that combines longitudinal oncology care with on-site therapeutics. For example, 99214 (1.5K claims, $145.3K revenue) and 99213 (819 claims, $54.9K revenue) show substantial office visit activity supporting the infusion services and drug administration workflow.

From a business perspective, the practice’s dependence on a single drug is meaningful: J9271 alone represents $3.1M and 52.1% of Total Medicare revenue. That concentration gives the provider strong negotiating relevance for pembrolizumab-related services and creates a strategic sensitivity to changes in utilization, clinical guidelines, or reimbursement for that agent, while the broader top-3 concentration (75.1%) underscores a focused oncology drug portfolio driving most Medicare revenue.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

65 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	71,200	$40	$3.1M
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	18,360	$40	$697.7K
J9299	Injection, nivolumab, 1 mg	27,080	$20	$649.9K
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	1,370	$160	$220.6K
J0897	Injection, denosumab, 1 mg	10,740	$20	$204.1K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	5,310	$40	$191.2K
J9304	Injection, pemetrexed (pemfexy), 10 mg	2,660	$60	$148.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,450	$100	$145.3K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,200	$100	$122K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	2,510	$30	$65.2K

Showing 1–10 of 65

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 65 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Florida Distribution

Syed Zafar — 10 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Florida

Full comparison — all codes billed, vs. state median

65 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	1	210	16,100	$40	$802.7K
J9299	18	70	15,580	$20	$423.9K
J9144	12	80	9,000	$40	$410.6K
J2353	2	10	1,400	$160	$225.6K
J1569	48	130	4,080	$40	$176.2K
J9304	1	10	2,660	$60	$147.6K
J0897	166	1,060	3,290	$20	$106.5K
J1449	38	40	3,560	$30	$99.2K
J0885	84	240	6,630	$10	$45.6K
96413	4	730	200	$100	$26.1K

Showing 1–10 of 65

Related Providers

Other providers that share a Tax Identification Number (TIN) with Syed Zafar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Florida Cancer Specialists & Research Institute, LLC	FL	Medical Oncology Physician	$0	$63.5M
Wilfredo Blasini	FL	Clinical Pathology Physician	$16.9M	$307.9K
Ryan Olson	FL	Anatomic Pathology & Clinical Pathology Physician	$12.8M	$80
Robert Mcdonald	AZ	Diagnostic Radiology Physician	$7.5M	$0
Christopher Lobo	FL	Medical Oncology Physician	$6.1M	$0
Ronald Goodwich	FL	Nuclear Medicine Physician	$5.7M	$0
Steven Newman	FL	Medical Oncology Physician	$5.7M	$0
Andrew Lipman	FL	Medical Oncology Physician	$5.6M	$0
Vijay Patel	FL	Medical Oncology Physician	$4.8M	$0
Jay Wang	FL	Medical Oncology Physician	$4.5M	$0

Nearby Providers

Other providers in the same ZIP code as Syed Zafar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Lee Memorial Health System	FL	Internal Medicine Physician	$0	$15.1M
Hope Hospice And Community Services Inc	FL	Community Based Hospice Care Agency	$0	$12.9M
Lee Memorial Health System	FL	Medically Fragile Infants and Children Day Care	$0	$7.4M
Veronica Papavero	FL	Anatomic Pathology Physician	$3.7M	$0
Raymond Esper	FL	Medical Oncology Physician	$3M	$0
Francisco Rodriguez	FL	Medical Oncology Physician	$2.7M	$0
Alan Brown	FL	Radiation Oncology Physician	$2.2M	$0
Keith Miller	FL	Radiation Oncology Physician	$1.7M	$0
William Harwin	FL	Medical Oncology Physician	$1.5M	$0
Graciela Garton	FL	Radiation Oncology Physician	$1.2M	$0

Syed Zafar — Billing Profile & Reimbursement Data

Sign up for Syed Zafar — Billing Profile & Reimbursement Data policy alerts

Syed Zafar — Billing Profile & Reimbursement Data

Sign up for Syed Zafar — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References